MX2007012688A - Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida. - Google Patents

Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.

Info

Publication number
MX2007012688A
MX2007012688A MX2007012688A MX2007012688A MX2007012688A MX 2007012688 A MX2007012688 A MX 2007012688A MX 2007012688 A MX2007012688 A MX 2007012688A MX 2007012688 A MX2007012688 A MX 2007012688A MX 2007012688 A MX2007012688 A MX 2007012688A
Authority
MX
Mexico
Prior art keywords
sub
optionally substituted
mol
bis
bonded
Prior art date
Application number
MX2007012688A
Other languages
English (en)
Inventor
Thomas A Dahl
Matthew Mcleod
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of MX2007012688A publication Critical patent/MX2007012688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un metodo para tratar a un sujeto con cancer, que incluye la etapa de co-administrar al sujeto durante tres a cinco semanas un taxano en una cantidad entre aproximadamente 243(mol/m2 a 315(mol/m2 (por ejemplo, equivalente a paclitaxel en aproximadamente 210-270mg/m2); y una bis(tiohidrazida amida) en una cantidad entre aproximadamente 1473(mol/m2 y aproximadamente 1722(mol/m2 (por ejemplo, el Compuesto (1) en aproximadamente 590-690mg/m2. La bis(tiohidrazida amida) esta representada por la Formula Estructural (I), Y es un enlace covalente o un grupo hidrocarbilo de cadena recta substituida opcionalmente, o, Y, tomada junto con ambos grupos >C=Z a los cuales esta unida, un grupo arilo opcionalmente substituido, o R1 y R2 tomados juntos con los atomos de carbono y nitrogeno a los cuales estan unidos, y/o R2 y R4 tomados junto con los atomos de carbono y nitrogeno a los cuales estan unidos, forman un anillo heterociclico no aromatico opcionalmente fusionado a un anillo aromatico, R7-R8 son independientemente H, un grupo alifatico substituido opcionalmente o un grupo arilo substituido opcionalmente, Z es 0 o S.
MX2007012688A 2005-04-15 2006-04-13 Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida. MX2007012688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67213905P 2005-04-15 2005-04-15
PCT/US2006/014531 WO2006113695A1 (en) 2005-04-15 2006-04-13 Combination cancer therapy with bis(thiohydrazide) amide compounds

Publications (1)

Publication Number Publication Date
MX2007012688A true MX2007012688A (es) 2008-03-14

Family

ID=36694110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012688A MX2007012688A (es) 2005-04-15 2006-04-13 Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.

Country Status (11)

Country Link
US (2) US8017654B2 (es)
EP (1) EP1877048A1 (es)
JP (1) JP2008536875A (es)
AU (1) AU2006236378B2 (es)
BR (1) BRPI0610219A2 (es)
CA (1) CA2604907A1 (es)
IL (1) IL186662A (es)
MX (1) MX2007012688A (es)
NZ (1) NZ562572A (es)
WO (1) WO2006113695A1 (es)
ZA (1) ZA200708703B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
ME01644B (me) * 2004-06-23 2014-09-20 Synta Pharmaceuticals Corp BIS(TIO-HIDRAZID AMIDNE) SOLl ZA TRETMAN KANCERA
CA2587598A1 (en) 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing hsp70 expression
MX2007012688A (es) 2005-04-15 2008-03-14 Synta Pharmaceuticals Corp Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.
WO2006113493A2 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
JP2008540658A (ja) 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）塩の合成
US7678832B2 (en) 2005-08-16 2010-03-16 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
AU2007288340A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
NZ575350A (en) 2006-08-21 2012-02-24 Synta Pharmaceuticals Corp Bis(phenylcarbonothioyl)hydrazide derivatives
WO2008024301A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
AU2007288334A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
WO2008033300A2 (en) * 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
WO2008033494A2 (en) 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US8482732B2 (en) * 2007-10-01 2013-07-09 Maskless Lithography, Inc. Alignment system for various materials and material flows
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
BRPI0919720A2 (pt) 2008-10-22 2015-12-08 Synta Pharmaceuticals Corp complexos de metal de transição de compostos bis-[tio hidrazida amida
CN102256949B (zh) 2008-10-22 2014-09-24 辛塔医药品有限公司 双[硫代酰肼酰胺]化合物的过渡金属络合物
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
AU2009322603B2 (en) 2008-12-01 2013-08-29 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2011069159A2 (en) 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
WO2011133673A1 (en) 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
EP2776021A1 (en) * 2011-11-10 2014-09-17 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20150057357A1 (en) 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH482394A (de) 1966-09-14 1969-12-15 Shell Int Research Herbizides Mittel
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (es) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US4826866A (en) * 1987-11-02 1989-05-02 A. H. Robins Company, Incorporated 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics
DE68904905T2 (de) * 1988-03-09 1993-07-22 Cis Bio Int Herstellung von als radiopharmazeutische produkte verwendbare nitruroverbindungen.
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DK0693924T4 (da) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
AU1257895A (en) * 1993-11-17 1995-06-06 Schepens Eye Research Institute, Inc., The Antibody to ocular and vaginal surface epithelium
CA2191999A1 (en) 1994-06-03 1995-12-14 Oliver Wagner Carbamoyl carboxylic acid hydrazides and their use against fungi
JPH08182050A (ja) 1994-12-27 1996-07-12 Matsushita Electric Works Ltd 無線通信システム
CA2166676C (en) * 1995-01-09 2007-05-01 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
EP0851874B1 (en) * 1995-09-22 1999-09-15 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US5753200A (en) * 1996-10-07 1998-05-19 Solvay Minerals, Inc. Sodium metabisulfite process
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
EP1387684A1 (en) * 2001-05-01 2004-02-11 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
EP1405841B1 (en) * 2001-06-20 2006-08-16 Kuraray Co., Ltd. Process for preparation of 2-oxocarboxylic acid esters
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
JP2005513035A (ja) * 2001-11-28 2005-05-12 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ５−スルファニル−４ｈ−１，２，４−トリアゾール誘導体及びその医薬としての使用
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
DK1611112T3 (da) 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
BRPI0509172A (pt) 2004-03-26 2007-08-28 Amphora Discovery Corp pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
ME01644B (me) 2004-06-23 2014-09-20 Synta Pharmaceuticals Corp BIS(TIO-HIDRAZID AMIDNE) SOLl ZA TRETMAN KANCERA
WO2006033913A2 (en) 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
CA2587598A1 (en) 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing hsp70 expression
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
JP5123671B2 (ja) 2005-02-17 2013-01-23 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための化合物
MX2007012688A (es) 2005-04-15 2008-03-14 Synta Pharmaceuticals Corp Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
US20090042991A1 (en) * 2005-04-15 2009-02-12 James Barsoum Methods of increasing natural killer cell activity for therapy
JP2008540658A (ja) 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）塩の合成
US7678832B2 (en) * 2005-08-16 2010-03-16 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
EP1954788B1 (en) * 2005-11-18 2013-09-18 Ferox, Inc. Biphenyl carrier for ferrocene catalysts and methods of using the same
SI22254A (sl) 2006-04-13 2007-10-31 Univerza V Ljubljani Fakulteta Za Farmacijo NOVI ARILSULFONOHIDRAZIDNI INHIBITORJI ENCIMOV MurC IN MurD
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AU2007288334A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US8497272B2 (en) 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008024301A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
NZ575350A (en) 2006-08-21 2012-02-24 Synta Pharmaceuticals Corp Bis(phenylcarbonothioyl)hydrazide derivatives
AU2007288340A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
WO2008033300A2 (en) 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
WO2008033449A2 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
WO2008033494A2 (en) 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
AU2007319851A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009020631A2 (en) 2007-08-07 2009-02-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
TW200940050A (en) 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)
EP2225201A2 (en) 2007-11-28 2010-09-08 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)

Also Published As

Publication number Publication date
IL186662A (en) 2014-01-30
IL186662A0 (en) 2008-06-05
NZ562572A (en) 2011-01-28
CA2604907A1 (en) 2006-10-26
AU2006236378A1 (en) 2006-10-26
EP1877048A1 (en) 2008-01-16
JP2008536875A (ja) 2008-09-11
US8017654B2 (en) 2011-09-13
ZA200708703B (en) 2008-11-26
AU2006236378B2 (en) 2010-12-02
WO2006113695A1 (en) 2006-10-26
US20090137682A1 (en) 2009-05-28
US20120232134A1 (en) 2012-09-13
BRPI0610219A2 (pt) 2010-06-08

Similar Documents

Publication Publication Date Title
MX2007012688A (es) Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.
HK1084024A1 (en) Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
WO2006055747A3 (en) Bis(thio-hydrazide amides) for increasing hsp70 expression
ATE533483T1 (de) Bis(thio-hydrazid amid) verbindungen in kombination mit taxol zur behandlung von krebs
TW200612895A (en) Bis(thio-hydrazide amide) salts for treatment of cancers
CY1117067T1 (el) Η χρηση σωματιδιων στερεων φορεων για τη βελτιωση της επεξεργασιμοτητας φαρμακευτικου παραγοντα
MX2009004715A (es) Compuestos heterociclicos como agentes antiinflamatorios.
CY1111190T1 (el) Παραγωγα μαλεϊμιδιου, φαρμακευτικες συνθεσεις και μεθοδοι για την θεραπεια καρκινου
ATE522249T1 (de) Organische verbindungen
JP2008535902A5 (es)
HK1145839A1 (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
UY32463A (es) Derivados de (1-{[5-(4-halo-2-trifluorometil-fenilamino)piridin-2-ilmetil]-carbamoil -ciclopropil)-amidas de ácidos pirimidin-carboxílicos y similares; sus enantiómeros, sus diastereoisómeros, y sus sales, fisiológicamente tolerables.
JP2017511321A5 (es)
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CY1112570T1 (el) Θεραπεια καρκινων με μετασταση
NO20091495L (no) Pyrazolopyrimidinderivat
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
CY1122608T1 (el) Θεραπευτικη αγωγη
ATE549313T1 (de) Verbindungen mit antitumorwirkung
EA201000807A1 (ru) Производные цефаломаннина, их приготовление, фармацевтические композиции и применение
CY1114194T1 (el) Αναστολεις δραστικοτητας ακτ

Legal Events

Date Code Title Description
FG Grant or registration